ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; and data communications and control products, such as EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:RMD
CUSIP76115210
Phone858-836-5000
Debt
Debt-to-Equity Ratio0.39
Current Ratio3.48
Quick Ratio2.85
Price-To-Earnings
Trailing P/E Ratio32.64
Forward P/E Ratio31.06
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.07 billion
Price / Sales7.55
Cash Flow$3.6202 per share
Price / Cash30.20
Book Value$13.82 per share
Price / Book7.91
Profitability
EPS (Most Recent Fiscal Year)$2.82
Net Income$342.28 million
Net Margins13.52%
Return on Equity23.72%
Return on Assets13.66%
Miscellaneous
Employees6,080
Outstanding Shares142,740,000
Market Cap$15,605.55
ResMed (NYSE:RMD) Frequently Asked Questions
What is ResMed's stock symbol?
ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."
How often does ResMed pay dividends? What is the dividend yield for ResMed?
ResMed announced a quarterly dividend on Thursday, April 26th. Stockholders of record on Thursday, May 10th will be given a dividend of $0.35 per share on Thursday, June 14th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date is Wednesday, May 9th. View ResMed's Dividend History.
How were ResMed's earnings last quarter?
ResMed Inc. (NYSE:RMD) posted its earnings results on Thursday, April, 26th. The medical equipment provider reported $0.92 EPS for the quarter, beating the Zacks' consensus estimate of $0.85 by $0.07. The medical equipment provider had revenue of $591.60 million for the quarter, compared to analysts' expectations of $575.75 million. ResMed had a return on equity of 23.72% and a net margin of 13.52%. The firm's quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter last year, the company earned $0.71 earnings per share. View ResMed's Earnings History.
When is ResMed's next earnings date?
What price target have analysts set for RMD?
13 brokerages have issued twelve-month price targets for ResMed's shares. Their predictions range from $55.00 to $90.00. On average, they anticipate ResMed's stock price to reach $68.80 in the next twelve months. This suggests that the stock has a possible downside of 37.1%. View Analyst Ratings for ResMed.
What is the consensus analysts' recommendation for ResMed?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 sell ratings, 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about ResMed stock?
Here are some recent quotes from research analysts about ResMed stock:
- 1. According to Zacks Investment Research, "Over the past three months, ResMed has outperformed its industry. The company achieved solid double-digit global revenue growth in the last reported quarter, led by sales from Software-as-a-Service businesses as well as new mask products and devices. The company is also focusing on product innovation through research and development. In terms of recent developments, the company recently received reimbursement approval for mandibular repositioning devices in France. Further, the company announced that South Korea will start reimbursing diagnosis and therapeutic treatment for sleep apnea in the near term. All these factors boost investor faith in the stock. Yet, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to challenging pricing scenario. Rising costs and a weak gross margin are other concerns." (7/16/2018)
- 2. Needham & Company LLC analysts commented, "We worked with Sleep Review magazine to survey US sleep centers. The survey included 136 responses received between 1/30/18 and 2/19/18. Compared to our prior (3Q17) survey, actual last-12-month patient volume growth decreased slightly while expected next-12-month patient volume growth increased slightly. RMD’s flow generator ratings were in line with Respironics’ ratings while RMD’s mask ratings were the highest but only slightly above its competitors’ ratings. RMD looks likely to gain branded flow generator prescription share but to lose branded mask prescription share. Overall, we think that the survey is mixed for RMD and we maintain our Hold rating." (3/7/2018)
Who are some of ResMed's key competitors?
Some companies that are related to ResMed include Boston Scientific (BSX), FRESENIUS SE &/S (FSNUY), Baxter International (BAX), ABIOMED (ABMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Haemonetics (HAE), Insulet (PODD), Globus Medical (GMED), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR) and Merit Medical Systems (MMSI).
Who are ResMed's key executives?
ResMed's management team includes the folowing people:
- Mr. Michael J. Farrell BE, SM, MBA, Chief Exec. Officer and Director (Age 46)
- Mr. Robert A. Douglas, Pres & COO (Age 58)
- Mr. Brett A. Sandercock, Chief Financial Officer (Age 51)
- Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 59)
- Mr. James Hollingshead, Pres of Sleep Bus. (Age 55)
Has ResMed been receiving favorable news coverage?
Press coverage about RMD stock has been trending somewhat positive on Sunday, Accern reports. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ResMed earned a daily sentiment score of 0.12 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 44.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are ResMed's major shareholders?
ResMed's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.38%), American Capital Management Inc. (0.45%), Capital Investment Services of America Inc. (0.11%), Bank of Montreal Can (0.09%), Gateway Investment Advisers LLC (0.08%) and Nisa Investment Advisors LLC (0.06%). Company insiders that own ResMed stock include Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Mchale, Richard Sulpizio, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.
Which institutional investors are selling ResMed stock?
RMD stock was sold by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., Baillie Gifford & Co., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Amalgamated Bank, Hartford Investment Management Co., Bank of Montreal Can, Nisa Investment Advisors LLC and Cape Cod Five Cents Savings Bank. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Peter C Farrell, Richard Mchale, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed.
Which institutional investors are buying ResMed stock?
RMD stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Cornerstone Wealth Management LLC, Denali Advisors LLC, Fox Run Management L.L.C., State of Alaska Department of Revenue, Addenda Capital Inc., Creative Planning and IFM Investors Pty Ltd. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.
How do I buy shares of ResMed?
Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ResMed's stock price today?
One share of RMD stock can currently be purchased for approximately $109.33.
How big of a company is ResMed?
ResMed has a market capitalization of $15.61 billion and generates $2.07 billion in revenue each year. The medical equipment provider earns $342.28 million in net income (profit) each year or $2.82 on an earnings per share basis. ResMed employs 6,080 workers across the globe.
How can I contact ResMed?
ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]
MarketBeat Community Rating for ResMed (NYSE RMD)
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
